MedTrace Logo

NK-1 Antagonism of SLV317 in Humans

NCT00160862 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2005-09-12

No results posted yet for this study

Summary

The primary objective is to determine the effect of a single oral dose of 250 mg SLV 317 on substance P-induced venodilation in the hand vein of healthy male volunteers as compared to placebo.

Conditions

  • Healthy

Interventions

DRUG

SLV317

Sponsors & Collaborators

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Walter E Haefeli, MD · Heidelberg University

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-05-31
Completion
2003-11-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00160862 on ClinicalTrials.gov